U.S. drugmaker Merck said on Thursday its experimental combination treatment for some adults with HIV-1 infection met the ...

Biotech giant Gilead Sciences, Inc. GILD has put up a steady performance in 2024 amid a volatile market. Its shares have ...

ICER's 2023 report highlights five drugs with unsupported price increases, leading to $815 million in excess costs for U.S.

The drug for which spending increased the most due to a price increase was Gilead’s HIV treatment Biktarvy. The company ...

GSK has fired a shot across the bows of Gilead Sciences' HIV juggernaut Biktarvy, with new data showing its rival therapy Dovato is as effective but causes less weight gain. The results of the ...

Investors are bullish on Gilead as the stock surges on successful launches and strong financial health, offering potential ...

INR:9445. teen patti taas Gilead's AIDS drug Biktarvy shows high viral suppression in Phase III clinical trial The Yangtze River Delta Sub-center of the National ...

For years, Gilead Sciences was dead money for shareholders. Shares of the drugmaker, with a market capitalization of just ...

Gilead Sciences, Inc. (NASDAQ:GILD), a biopharmaceutical company, discovers, develops and commercializes medicines to address ...

The Maine Bureau of Insurance announced Monday that the carrier reversed its initial decision and will cover eight HIV ...